CompuVax, Inc. announces issuance of two US Patents for key RSV antigens
Del Mar, August 1, 2017
CompuVax, Inc. announces the issuance of two United States Patents on antigens against the respiratory syncytial virus engineered at Bill Schief's laboratory. United States Patent No 9,718,862 B2 claims key epitope-scaffold immunogens against the respiratory syncytial virus and was issued on August 1, 2017 with a duration until October 5, 2031. United States Patent No 9,701,720 B2 claims improved variants in terms of size, stability, affinity, and resistance to mutant viruses. It was issued on July 11, 2017 and its duration is until April 4, 2033. Both patents were issued to the University of Washington and are exclusively licensed worldwide to CompuVax, Inc.